Professor, Chief Scientific Officer University of Colorado
Dr. Leinwand is a Distinguished Professor of Molecular, Cellular, and Developmental Biology (MCDB) and the Chief Scientific Officer of the BioFrontiers Institute at the University of Colorado Boulder. Her research laboratory focuses on the genetics and molecular physiology of inherited diseases of the heart and particularly how biological sex affects the heart in health and disease. She co-founded Myogen, Inc. (acquired by Gilead Pharmaceuticals), Hiberna, Inc., and MyoKardia, Inc. (acquired by Bristol Myers Sqibb), which develop therapeutics for inherited cardiomyopathies. She is a Fellow of the AAAS, a former MERIT Awardee of the NIH, an Established Investigator of the American Heart Association, and an elected member of the American Academy of Arts and Sciences and the National Academy for Inventors.